Results from Novel Phase III Studies in Soft Tissue Sarcomas

Speaker: Olivier Mir

O. Mir elaborates results from trials in soft tissue sarcomas (STS) presented at ASCO 2015. He discuss the results from evaluation of gemcitabine and docetaxel vs doxorubicin as first-line therapy in advanced (unresectable or metastatic) STS; eribulin vs dacarbazine in leiomyosarcoma and adipocytic sarcoma; and trabectedin or dacarbazine for advanced liposarcoma or leiomyosarcoma. He provides an expert opinion on potential drug approvals as an outcome of these studies.

Discussion Points

  • GeDDiS: Gemcitabine and docetaxel vs doxorubicin as first-line treatment in advanced unresectable or metastatic soft tissue sarcomas (Abstract #10500)
  • Eribulin vs dacarbazine in leiomyosarcoma and adipocytic sarcoma (Abstract #LBA10502)
  • Trabectedin or dacarbazine for the treatment of advanced liposarcoma or leiomyosarcoma (Abstract #10503)